Private limited company · Oslo
CALLUNA PHARMA AS
ActiveResearch and experimental development on natural sciences and engineering (72.100)
The life line 2023–2026
Operating revenue per year, with recorded events above. As a table
Operating revenue 2025: NOK 36.3m.
Sources: the Register of Company Accounts (company accounts), fetched 1 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.
In brief
CALLUNA PHARMA AS is a private limited company in Oslo, founded in 2023, in the industry research and experimental development on natural sciences and engineering. The chief executive is Mark William-Semrau Gaffney, and the chair of the board is Mark Frederick Altmeyer. In 2025 the company had NOK 36.3m in operating revenue and a net profit of NOK −10.1m. The largest owner is CALLUNA PHARMA POOLCO AS with 34.9%.
Put together by Intelligo from the sections below; each figure stands with its source where it belongs.
Overview
§ 01 Latest changes
4 changes, latest 13 Nov 2026
- Number of employees 10 → 9
- Changed capital 104166995 → 123667000
- Changed capital 1041669.95 → 1236670
- New articles of association 11 Sep 2026
Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →
Overview
§ 02 Worth knowing
2 points
- NoteChanged auditor 5 Oct 2026
- OKEquity ratio 83.9%, above the industry median
Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate
Overview
§ 03 Key figures
Revenue NOK 36.3m in 2025
Revenue
NOK 36.3m
+35.1% from 2024
20232025
Operating profit
NOK −16.0m
+39.9% from 2024
20232025
Net profit
NOK −10.1m
+14.8% from 2024
20232025
Equity
NOK 1.1bn
+44.0% from 2024
20232025
Source: the Register of Company Accounts, read 1 Nov 2026 · The full accounts →
Finances
§ 04 Where the money comes from and goes
Financial year 2025
Of every krone of operating revenue in 2025:
- Operating costs 144%
Costs exceeded revenue: the operating result was NOK −16.0m.
Source: the Register of Company Accounts, read 1 Nov 2026
Finances
§ 05 Financial health
Equity ratio 83.9%
- CALLUNA PHARMA AS, 2025
- Industry median, assumed: NOK 1.5m · −4.4% · 48.9% · +3.0%
Equity NOK 1.1bn84% of the assets (NOK 1.3bn)
Source: the Register of Company Accounts, read 1 Nov 2026. The median is derived by Intelligo from 694 companies in 72.100 Research and experimental development on natural sciences and engineering, not stated by the source.
Finances
§ 06 Accounts
2 years, latest 2025
| NOK 1,000 | 2024–25 | 2025 | 2024 |
|---|---|---|---|
| Operating revenue | 36,344 | 26,905 | |
| Operating profit | −16,004 | −26,638 | |
| Profit before tax | −10,145 | −11,911 | |
| Net profit | −10,145 | −11,911 | |
| Total assets | 1,319,877 | 853,584 | |
| Equity | 1,107,692 | 769,267 | |
| Liabilities | 212,185 | 84,317 |
Source: the Register of Company Accounts, read 1 Nov 2026 · All 2 years →
Management and ownership
§ 07 Officers
10 officers now
- Mark William-Semrau GaffneyChief executive since 2024
- Mark Frederick AltmeyerChair of the board since 2024
- PRICEWATERHOUSECOOPERS ASAuditor since 2026
- ADVIS ASAccountant
- Susanne StuffersBoard member since 2024
- ENORA ASAccountant
Source: the Brønnøysund Register Centre, read 30 Oct 2026 · All 10 roles, former ones too →
Management and ownership
§ 08 Signature, procuration and authorisations
Styrets leder og ett styremedlem i fellesskap.
May sign for the company:
Styrets leder og ett styremedlem i fellesskap.
Procuration: none registered.
The board has 1 authorisation in force now: capital increase, until 23 May 2027.
The signature is word for word from the register. Source: the Register of Business Enterprises, read 5 Oct 2026
Management and ownership
§ 09 Owners
3 shareholders · largest 34.9%
| Owner | Share |
|---|---|
| CALLUNA PHARMA POOLCO AS | 34.9% |
| CALLUNA PHARMA POOLCO AS | 0.7% |
| CALLUNA PHARMA POOLCO AS | 0.4% |
Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 30 Jul 2026 · All 3 owners →
Management and ownership
§ 10 Group
1 subsidiary
Share held. Source: the Tax Administration's shareholder register, fetched 30 Jul 2026 · The whole group →
Management and ownership
§ 11 Portfolio
None registered
No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.
Management and ownership
§ 12 Network
11 connections
- Person
- Company
3 people link CALLUNA PHARMA AS to 9 other companies: Susanne Stuffers 4, Farzad Abdi-Dezfuli 3 and Mark William-Semrau Gaffney 2.
Source: the Brønnøysund Register Centre, read 30 Oct 2026 · Explore the network →
Events and registers
§ 13 Events
33 since 2023
Events per year
20232026
Since 2023: 28 announcements and 5 register changes. Most happened in 2024 and 2026.
Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 2 Nov 2026. Register changes are Intelligo's own observations. · All 33 events →
Events and registers
§ 14 Notices
28, latest 28 Oct 2026
- Kapital
- Vedtektsdato
- Revisor
Source: The Brønnøysund Register Centre's announcements ↗, read 2 Nov 2026 · All 28 →
Events and registers
§ 15 Charges
Not fetched yet
Events and registers
§ 16 Other registers
Found in 3 of 7
- The Central Coordinating RegisterRegistered 14 Oct 2023
- VATRegistered
- The Register of Business EnterprisesRegistered 14 Oct 2023
- The Cleaning RegisterNot registered
- The Register of Staffing AgenciesNot registered
- Smiley scheme, the Norwegian Food Safety AuthorityNot registered
- The Financial Supervisory Authority's licence registerNot registered
Purpose: Å investere i farmasøytiske selskaper og virksomheter, herunder å realisere slike investeringer, samt all annen virksomhet knyttet til dette.
Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026
Market
§ 17 Tenders
None registered
No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.
Market
§ 18 Vacancies
None registered
No vacancies.No open ads at NAV. Checked 15 Nov 2026.
Market
§ 19 Competitors
Industry code 72.100
The companies most like it:
Compare themThe selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →
Last
§ 20 Questions and answers
7 questions
- Who is the chief executive of CALLUNA PHARMA AS?
Mark William-Semrau Gaffney, since 2024. § 07 - Who owns CALLUNA PHARMA AS?
3 shareholders. The largest is CALLUNA PHARMA POOLCO AS with 34.9%, CALLUNA PHARMA POOLCO AS with 0.7% and CALLUNA PHARMA POOLCO AS with 0.4%. § 09 - What was the revenue in 2025?
NOK 36.3m in the company. § 06 - Who can sign for CALLUNA PHARMA AS?
Styrets leder og ett styremedlem i fellesskap. § 08 - Who is the auditor?
PRICEWATERHOUSECOOPERS AS, from 5 Oct 2026. § 07 - Where is CALLUNA PHARMA AS based?
Gaustadalléen 21, 0349 Oslo. - When was CALLUNA PHARMA AS founded?
1 Sep 2023, registered in the Register of Business Enterprises 14 Oct 2023. § 16
The answers come from the sections linked to, with their sources.